Our board

Mark is Chief Executive Officer of CHEMAI Ltd and is an advisor to Angelini Ventures. He is widely recognised in the UK and international life sciences sector, having spent almost 10 years at IP Group Plc, a leading intellectual property commercialisation company, where he led the Healthcare team. 

Appointment to Board:
September 2016

Bram has over 20 years of leadership in BioPharma and precision medicine. He held C-level roles at Eagle Genomics and SOPHiA Genetics, enhancing platform innovation and US presence. As VP at Foundation Medicine, he expanded its global precision medicine platform. As CEO of Prometheus Laboratories, he integrated it into Nestle Health Science and served as Head of Brain Health. Earlier, he held senior roles at UCB Pharma and Eli Lilly, launching CNS medicines globally. Bram’s board experience includes Mantis Photonics and Cerecin Inc. He is passionate about patient care and values diverse teams. His strategic vision and leadership have consistently driven growth and shareholder value.

Appointment to Board:
August 2024

Grant has worked in the life sciences sector for over 20 years. In his executive director role, Grant leads the Company's Finance, Legal and IT functions. Grant joined IXICO from UK Biobank, an international health research data resource, where he had been Finance Director since 2014. Previous to this, he qualified as a Chartered Accountant at PwC and was SVP Finance at Evotec, the early stage drug discovery CRO. Grant is a member of the Share Transaction Committee and also acts as Secretary to the Board and its subcommittees.

Appointment to Board:
August 2019

Kate is the CEO of the Follicular Lymphoma Foundation which she joined in 2022 following a 20-year career with Glaxo SmithKline.  At GSK, Kate led the transformation of GSK’s global finance organisation, having previously worked as CFO for Laboratoire Glaxo SmithKline SaS (GSK France) and other senior finance roles within GSK.  Kate is qualified as a chartered accountant and holds a Bachelor of Science degree in Engineering from Oxford University. Kate chairs the Audit Committee and is a member of the Remuneration Committee.

Appointment to Board:
January 2022

Dipti is an experienced non-executive director.  She currently sits on the Board of Lineage Cell Therapeutics, a US based biotechnology company, having previously sat on the Boards of companies in both the private and public sector.  Before this, Dipti spent over 20 years of her executive career at IQVIA occupying senior positions in compliance, drug safety and medical affairs.  Dipti is medically trained and is a Fellow of the Faculty of Pharmaceutical Medicine.  Dipti is Chair of the Remuneration and Share Transaction Committees and a member of the Audit Committee.

Appointment to Board:
October 2023